ABBV News 55.00 06/26/2014 04:21:38 Abbvie Inc. Common Stock

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Abbvie Inc. Common Stock (ABBV) 55.00 $ABBV

Stocks Hold Modest Gains; Shire Hits New High
at Investor's Business Daily - Wed Jun 25, 12:23PM CDT
Stocks continued to hold modest gains Wednesday afternoon after shaking off early losses caused by disappointing economic data. The Nasdaq and the S&P 500 were up 0.4% and 0.3%, respectively. Meanwhile, the Dow Jones industrial average was up 0.2%....

AbbVie cites tax break as a Shire deal motivator
By TOM MURPHY - AP - Wed Jun 25, 11:50AM CDT
U.S. drugmaker AbbVie sees a compelling tax break behind its roughly $46 billion bid to buy British counterpart Shire, and it expects the deal to expand Shire's global reach as well.

Why AbbVie (ABBV) Stock Is Gaining Today
at The Street - Wed Jun 25, 10:17AM CDT
Shares of AbbVie (ABBV) are up after the pharmaceuticals company presented its strategic rationale for acquiring Shire (SHPG).

Will Shire's Growth Plan Motivate AbbVie to Dig Deeper?
Cheryl Swanson, The Motley Fool - Motley Fool - Wed Jun 25, 8:30AM CDT
The market is already looking for AbbVie Inc to sweeten its recently rejected cash-and-shares offer of $46.5 billion for British drug maker Shire . But, by how much? And, assuming AbbVie comes up with yet another offer, will it be enough to...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
PR Newswire Europe - Wed Jun 25, 7:47AM CDT
- Materials for analyst and investor call in respect of possible offer for Shire plc

Vertex's Price Pop by the Numbers: Does It Fly?
Alex Dumortier, CFA, The Motley Fool - Motley Fool - Tue Jun 24, 8:44PM CDT
U.S. stocks finished lower on Tuesday, with the benchmark S&P 500 closing down 0.6%, while the narrower Dow Jones Industrial Average lost 0.7%. The technology-heavy Nasdaq Composite Index fell 0.1%. One Nasdaq component had a banner day,...

Should Dividend Investors Eject AbbVie Stock?
David Williamson, The Motley Fool - Motley Fool - Tue Jun 24, 6:01PM CDT
Dividend aristocrat spin-off AbbVie  (NYSE: ABBV) has one of the highest yields in health care, but does that make it one of the sector's top dividend stocks?  In this video, Motley Fool Healthcare analyst David Williamson will be grading well...

Takeover Tango: Healthcare's Best Dance Partner Is...
Keith Speights, The Motley Fool - Motley Fool - Tue Jun 24, 4:00PM CDT
Buying a drug company ain't what it used to be. Once upon a time, a larger pharmaceutical firm would make an offer for a smaller company. Said smaller drugmaker would swoon at the immediate gains for its shareholders. The deal would go through --...

AbbVie Raises Outlook amidst Shire Takeover Attempts - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 3:40PM CDT
AbbVie Inc. (ABBV), which is currently looking to buy UK-based Shire (SHPG), raised its 2014 adjusted earnings guidance.

Abbott Labs to Buy Russia-Based Veropharm - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 3:15PM CDT
Abbott Laboratories (ABT) announced a definitive agreement to acquire Russia-based pharmaceutical manufacturer Veropharm for approximately $395 million to $495 million.

Walgreen Mulls Overseas Tax Move After Earnings Miss
at Investor's Business Daily - Tue Jun 24, 3:04PM CDT
Walgreen (WAG) missed third-quarter earnings forecasts, but shares pared losses Tuesday after the drug store giant confirmed for the first time that it is mulling a move overseas to cut taxes. The No. 1 drug retailer in the U.S. earned 91 cents a...

AstraZeneca Gets a Chance to Prove Its Worth to Pfizer
Brian Orelli, The Motley Fool - Motley Fool - Tue Jun 24, 1:09PM CDT
A company that rejects a buyout proposal with a 45% stock-price premium had better deliver on its case for  being worth more than the offer. AstraZeneca gets an early shot to prove its worth tomorrow when a Food and Drug Administration's...

Epithelial Ovarian Cancer - Pipeline Review, H1 2014
M2 - Tue Jun 24, 4:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5l7bgr/epithelial) has announced the addition of the "Epithelial Ovarian Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Epithelial Ovarian Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Epithelial Ovarian Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Epithelial Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Epithelial Ovarian Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - Boehringer Ingelheim GmbH - Amgen Inc. - Oxford BioMedica plc - Millennium Pharmaceuticals, Inc. - ImmunoGen, Inc. - Bayer AG - Pharmacyclics, Inc. - Prima BioMed Ltd. - Synta Pharmaceuticals Corp. - Oasmia Pharmaceutical AB - Glycotope GmbH - TRION Pharma GmbH - BioNumerik Pharmaceuticals, Inc. - CerRx, Inc. - Immunotope, Inc. - Pharma Mar, S.A. - VentiRx Pharmaceuticals, Inc. - Clovis Oncology, Inc. - Recepta Biopharma S.A. - California Stem Cell, Inc. - EGEN, Inc. - AbbVie Inc. - Sotio a.s. For more information visit http://www.researchandmarkets.com/research/5l7bgr/epithelial
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Youdao Profit Holds, but Revenue and Cash Raise Flags

Updated Category News Views 70

Profitability Arrived With a Few Splinters A shrinking top line wearing a profit badge is never an easy thing to applaud. Youdao delivered RMB1.4 billion in third-quarter 2026 revenue, or US$213.1 million, down 12.3% from a year earlier. Yet income from operations climbed 19.2% to RMB33.7 million, making this the company’s ninth consecutive quarter of operating...

Continue Reading
Five Films Put Modern Infrastructure Under a Lens

Updated Category News Views 121

Most infrastructure only earns a thought when it breaks, and that is precisely the nerve these films are trying to touch. Nicely Done Productions has released the final five installments of its ten-part Threads of Connectivity documentary series, hosted on National Geographic's global digital platform. The subjects are illycaffè, Cargill, Honeywell Aerospace, Western...

Continue Reading
FLX Opens a New Door to Pre-IPO Deal Flow for Advisors

Updated Category News Views 160

Private-market chatter has been leaking past the velvet rope for years, and advisors are sick of learning about it after a client already has a pitch deck in hand. FLX Networks is responding to that irritation by letting its eligible advisor and wealth-management members review select pre-IPO opportunities shared by other members. Announced November 19, 2026, the move is...

Continue Reading
Botanica’s Illuminations Carries More Than Holiday Glow

Updated Category News Views 29

Two million lights are doing more than brightening up a few winter evenings in Wichita. Illuminations at Botanica returns from November 23, 2026, through January 2, 2027, and the pleasant part of this story is that the spectacle has a practical backbone: it is Botanica’s largest fundraiser. For a garden nonprofit, that matters a whole lot more than another shiny...

Continue Reading
Why Professional Collaboration May Matter More in AI

Updated Category News Views 33

Three smart professionals can still hand a client a mess when nobody owns the handoff. That unglamorous reality sits behind the Professional Collaboration Institute, or PCI, which Sarano and Brooke Kelley plan to launch in a virtual briefing on December 2. The outfit wants to turn cross-profession coordination into a teachable, measurable discipline rather than leave it...

Continue Reading
AT&T's Dec. 8 UBS Chat Puts Stankey's Updates on Watch

Updated Category News Views 98

A Small Slot With a Big Audience A calendar entry can still matter when the man holding the microphone runs AT&T. John Stankey, AT&T chairman and chief executive, is scheduled for a fireside chat at the UBS Global Media and Communications Conference on Tuesday, Dec. 8, beginning at 8:15 a.m. Eastern time. The company says the event will be webcast live through its...

Continue Reading
Pennsylvania Rebate Rules Matter Before Year-End Filing

Updated Category News Views 105

A missed rebate form can sting harder than most people expect, especially when a household has already spent the year watching property taxes, rent, groceries, and every other stubborn bill chew through fixed income. Pennsylvania’s Property Tax/Rent Rebate Program is not glamorous, and it is certainly not an investing story. It is, however, the kind of direct household...

Continue Reading
Africa’s Digital Ownership Debate Gets More Serious

Updated Category News Views 70

Ownership was the uncomfortable word hanging over Cape Town on day two of Africa Tech Festival 2026, and frankly it should make investors sit up. Africa’s digital economy has no shortage of big promises, shiny AI demos or overseas executives talking about opportunity. The harder question is who funds the pipes, owns the data, makes the rules and actually keeps the...

Continue Reading
Lowe's Dec. 9 Conference Puts Strategy on the Clock

Updated Category News Views 95

A Calendar Entry With Real Weight December 9 is not earnings day, but it is the sort of date shareholders ought to circle anyway. Lowe's plans to hold its 2026 Analyst and Investor Conference at 8 a.m. Eastern time in New York City, with a live webcast available for those not sitting in the room. For owners of NYSE:LOW, these gatherings can be more useful than the usual...

Continue Reading
Zoomlion’s Australian Service Push Looks Built to Last

Updated Category News Views 163

Five Australian business centres are one thing; getting a stalled crane or earthmover moving again is the whole ballgame. Zoomlion’s Nov. 4 customer gathering in Sydney matters because Chairman and CEO Zhan Chunxin kept the discussion on the unglamorous stuff: product quality, technical support, parts availability and local training. That is exactly where an equipment...

Continue Reading

Top 5 Most Recently Viewed Articles

Unlocking Digital Services for 627 Million People Worldwide

Updated Category News Views 94

Harnessing Digital Opportunities for the Excluded Population In an era where digital connectivity is vital for success, a significant portion of the global population remains disconnected. This is not just a statistic but a call to action as we face the reality that over 627 million people worldwide are still excluded from essential digital services. This number surpasses...

Continue Reading
Game-Changing Investment in Cancer Treatment by First Ascent Biomedical

Updated Category News Views 105

Revolutionary Investment in Cancer Treatment First Ascent Biomedical, celebrated for its advanced approach to personalized cancer therapy, has recently secured an impressive $6 million investment from Vidal Duart Enterprises, Inc. This funding marks a significant stride for the company as it aims to reshape the landscape of medical oncology. Accompanying this investment,...

Continue Reading
Ameris Bancorp Plans Q3 2024 Earnings Announcement Soon

Updated Category News Views 63

Ameris Bancorp Set to Reveal Third Quarter Earnings Ameris Bancorp, a notable financial institution with a significant presence in the Southeast, has announced its plans to release third quarter 2024 earnings. The company will share its financial results via a press release following the market close on a Thursday, in late October. This strategic timing aligns with the...

Continue Reading
Key Leadership Change at Amerant Bank Enhances Credit Oversight

Updated Category News Views 226

Amerant Bank Welcomes Jeffrey K. Tischler Amerant Bank, known for its strong reputation in the banking sector, has announced a significant addition to its executive team. Jeffrey K. Tischler has been appointed as the Senior Executive Vice President and Chief Credit Officer. This crucial role involves overseeing the bank's Credit Services, Portfolio Management, and Credit...

Continue Reading
Modera South Shore Begins Preleasing: Modern Living Awaits

Updated Category News Views 229

Modera South Shore: A New Era of Living Modera South Shore is set to transform contemporary living with the addition of 270 stylish homes to a friendly community. Nestled in a charming seaside setting, this modern garden-style community is positioned ideally for those seeking a balanced lifestyle. With a thoughtful design aimed at both comfort and elegance, it promises to...

Continue Reading